Text Size

A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides

This study is currently recruiting participants.
Verified January 2013 by Allergan
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01777620
First received: January 25, 2013
Last updated: NA
Last verified: January 2013
History: No changes posted
  Purpose

This is a safety and efficacy study of BOTOX® in subjects with facial rhytides (glabellar lines and crow's feet lines).


Condition Intervention Phase
Facial Rhytides
 Biological: onabotulinumtoxinA
Drug: Normal Saline
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Percentage of Subjects Satisfied with Treatment Using the Facial Line Satisfaction Questionnaire (FLSQ) [ Time Frame: Day 60 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of Subjects Satisfied with Duration of Treatment Results Using the FLSQ [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
  • Percentage of Subjects Reporting Likely Continued Treatment Using the FLSQ [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
  • Investigator's Assessment of the Severity of Glabellar Lines Using a 4-Point Scale [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
  • Investigator's Assessment of the Severity of Crow's Feet Lines Using a 4-Point Scale [ Time Frame: Day 30 ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: January 2013
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: BOTOX®
BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
 Biological: onabotulinumtoxinA
BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
Other Names:
  • botulinum toxin Type A
  • BOTOX®
  • BOTOX® Cosmetic
Placebo Comparator: Placebo
Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
 Drug: Normal Saline
Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glabellar lines and crow's feet lines
  • No prior use of botulinum toxin therapy of any serotype for any reason

Exclusion Criteria:

  • Previous facial cosmetic surgery, tissue grafting, or tissue augmentation with silicone or fat or other permanent fillers
  • Planning a facial cosmetic procedure during the study period
  • Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, and/or amyotrophic lateral sclerosis
  • Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01777620

Contacts
Contact: Allergan Inc. clinicaltrials@allergan.com

Locations
Canada, Ontario
Recruiting
Toronto, Ontario, Canada
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan
  More Information

No publications provided

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01777620     History of Changes
Other Study ID Numbers: GMA-BTXC-12-001
Study First Received: January 25, 2013
Last Updated: January 25, 2013
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Facies
Disease Attributes
Pathologic Processes
Botulinum Toxins, Type A
Botulinum Toxins
Neuromuscular Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013